Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Equity Dilution DNTH has strong liquidity and minimal debt, but persistent losses, cash burn, dilution, and an extreme sales multiple make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: • Lower highs • Support defense • Weak momentum Support Level: $103–$105 Resistance Level: $109–$110 DNTH remains in a short-term downtrend over the last month, with $103–$105 support holding but a sustained break above $109–$110 needed to improve momentum.
Sentiment & News
Key News Insights: • Investor Outreach • Institutional Buying • Pipeline Positioning Dianthus is boosting investor visibility and hiring momentum while gaining institutional backing and favorable attention for its autoimmune pipeline.
AI Summary
DNTH's $1.2B cash position removes near-term financing risk and shifts the investment thesis squarely to December 2026 MMN data and CIDP execution: positive, differentiated claseprubart results could validate a multi-indication platform, while weak or delayed data would expose its high valuation and rising burn.
Description
Dianthus Therapeutics is a clinical‑stage biotechnology firm developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is in Phase 1 clinical trials for generalized myasthenia gravis and several immune‑mediated neuropathies. The company was founded in 2015 and is based in New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 9 | Mar 16 | DNTH | Dianthus Therapeutics, Inc. | Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days. | Closed | -1.6% |